Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Efficacy of hUC-MSCs for ARDS
NCT06505941Phase 2Not yet recruiting
- Sponsor
- Southeast University
- Start
- Jul 2024
- Primary completion
- Nov 2025
- Modality
- Stem Cell Therapies
01
Overview
Phase 2, randomised, double-blind trial of human umbilical cord mesenchymal stem cells in acute respiratory distress syndrome (ARDS) (2 arms), sponsored by Southeast University. Primary endpoint: Safety of umbilical cord mesenchymal stem cell therapy at 48 weeks. Planned start Jul 2024; status: not yet recruiting.
02
Drugs
human umbilical cord mesenchymal stem cells
03
Conditions
acute respiratory distress syndrome (ARDS)
Beyond the preview
Go deeper on NCT06505941.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06505941.